Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta-analysis

Cancer Science

Volumn 105, Issue 8, 2014, Pages 1008-1014

  Cao, Chunxiang ^a   Zhang, Xunlei ^b   Kuang, Meng ^a   Gu, Dongying ^a   He, Mingliang ^c   Chen, Jinfei ^a   Tang, Cuiju ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

5 Fluorouracil; Chemotherapy; Gastrointestinal cancer; Meta analysis; S 1

Indexed keywords

FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASIAN; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FATIGUE; HUMAN; LEUKOPENIA; META ANALYSIS; METASTATIC COLORECTAL CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA;

5-FLUOROURACIL; CHEMOTHERAPY; GASTROINTESTINAL CANCER; META-ANALYSIS; S-1;

ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG COMBINATIONS; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; OXONIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TEGAFUR; TREATMENT OUTCOME;

EID: 84906568602     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12465     Document Type: Article

References (29)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
2. Spazzapan S, Crivellari D, Bedard P et al. Therapeutic management of breast cancer in the elderly. Expert Opin Pharmacother 2011; 12: 945-60.
3. Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmacother 2011; 12: 517-31.
4. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004; 15: 85-106.
5. Heidelberger C, Chaudhuri NK, Danneberg P et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-6.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
7. Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 2014; 20: 3905-15.
8. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
9. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
10. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288-323.
11. Maroun J, Asche C, Romeyer F et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003; 21: 1039-51.
12. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003; 7: 1-93.
13. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009; 39: 2-15.
14. Huang D, Ba Y, Xiong J et al. A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer 2013; 49: 2995-3002.
15. Baba H, Muro K, Yasui H et al. Updated results of the FIRIS study: a phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC) [Abstract]. J Clin Oncol 2011; 29: 3562.
16. Jin M, Lu H, Li J et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study [Abstract]. J Clin Oncol 2008; 26: 4533.
17. Otsuji T, Yamazaki K, Ojima H et al. Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC) [Abstract]. J Clin Oncol 2012; 30: 586.
18. Xu R, Sun G, Lu H et al. A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma [Abstract]. J Clin Oncol 2013; 31: 4025.
19. Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-9.
20. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
21. Muro K, Boku N, Shimada Y et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-60.
22. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-37.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
25. Yamada Y, Takahari D, Matsumoto H et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14: 1278-86.
26. Andoh H, Kato S, Gamoh M et al. A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 plus bevacizumab (IRIS+BV) and modified FOLFIRI plus BV (mFOLFIRI+BV) in patients (pts) with metastatic colorectal cancer (mCRC): the result of efficacy report of T-CORE0702 [Abstract]. J Clin Oncol 2011; 29: e14001.
27. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012; 13: 1943-59.
28. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-53.
29. Liu L, Cao Y, Tan A, Liao C, Gao F. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 2010; 65: 849-61.